Research graph
References from Proton pump inhibitors and durvalumab in PACIFIC – Authors' reply. Local targets link to admitted publications; unresolved targets remain external evidence.
Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial
10.1016/s1470-2045(26)00191-9 · 2026 · External reference
Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer
10.1200/jco.21.01308 · 2022 · External reference
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
10.1056/nejmoa1709937 · 2017 · External reference
Pretreatment risk model for radiation-induced lymphopenia is associated with adjuvant durvalumab efficacy in patients with unresectable stage III NSCLC
10.1016/j.ijrobp.2026.02.238 · 2026 · External reference
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice
10.1136/jitc-2020-001361 · 2020 · External reference
